Rigel Pharmaceuticals Inc. RIGL
Biotechnology: Pharmaceutical Preparations · IPO 2000 · data as of November 13, 2026
Rigel Pharmaceuticals Inc. (RIGL) is a healthcare company listed in the US with a market value of about $837M. In the twelve months to September 30, 2026 it had revenue of $288M and net income of $307M, a net margin of 106.6%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 2.8, a price to free cash flow of 43.2, 5-year revenue growth of 22% a year, a 5-year average ROIC of -35%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% above the current price.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2000. Revenue went from $20M in 2016 to $294M in 2025, growth of about 34.5% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 11% over three years (dilution for shareholders). It spends 11% of revenue on research and development.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/FCF below 20
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Pays a dividend
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $288M | $294M | $179M | $117M | $120M | $149M | $109M | $59M | $45M | $4M | $20M |
| Net income | $307M | $367M | $17M | -$25M | -$59M | -$18M | -$30M | -$67M | -$70M | -$78M | -$69M |
| Free cash flow | $19M | — | — | — | -$74M | $5M | -$53M | -$43M | -$60M | -$78M | -$77M |
| EPS (diluted) | $16.07 | $19.48 | $0.99 | $-1.44 | $-3.44 | $-1.11 | $-1.82 | $-4.04 | $-4.45 | $-6.27 | $-7.38 |
| Net margin | 106.6% | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% | -1739.3% | -339.6% |
| ROIC | — | 22.3% | 36.2% | -63.4% | -154.0% | -16.2% | -31.2% | -60.1% | -52.3% | -62.5% | -100.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $64.40, 45% above the current price; targets range from $47.00 to $86.00; the consensus rating is “Buy”; expected EPS is $3.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Rigel Pharmaceuticals’s P/E ratio?
About 2.8, based on the last twelve months of diluted earnings per share (forward P/E about 11.1).
Is Rigel Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Rigel Pharmaceuticals pay a dividend?
Not currently.
Is Rigel Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Rigel Pharmaceuticals scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.